An optimized BRD4 inhibitor effectively eliminates NF-κB-driven triple-negative breast cancer cells.
Sign Up to like & getrecommendations! Published in 2021 at "Bioorganic chemistry"
DOI: 10.1016/j.bioorg.2021.105158
Abstract: Acetylation of NF-κB's RelA subunit at lysine-310 (AcLys310) helps to maintain constitutive NF-κB activity in cancers such as triple-negative breast cancer (TNBC). Bromodomain-containing factor BRD4 binds to acetylated RelA to promote the activity of NF-κB.… read more here.
Keywords: acetylated rela; negative breast; breast cancer; brd4 ... See more keywords